CD4 and familial dilated cardiomyopathy: Abdullah and colleagues investigated the effects of fingolimod treatment in STZ-induced DCM mouse models and found that treatment resulted in a reduction in the number of CD4+ and CD8+ T cells and a suppression of cardiac fibrosis (82).